Details of the Drug-Related molecule(s) Interaction Atlas

O-Phosphoethanolamine Drug Info

2-Aminoethyl dihydrogen phosphate; O-Phosphorylethanolamine; 1071-23-4; O-Phosphocolamine; Colamine phosphate; Phosphorylethanolamine; ethanolamine phosphate; Phosphonoethanolamine; Ethanolamine O-phosphate; Mono(2-aminoethyl) phosphate; Phosphoryethanolamine; COLAMINE PHOSPHORIC ACID; Colaminephosphoric acid; Pe 104; Colaminphosphoric acid; Ethanol, 2-amino-, phosphate; Ethanolamine acid phosphate; Ethanol, 2-amino-, dihydrogen phosphate (ester); monoaminoethyl phosphate

Cross-matching ID

PubChem CID

1015

ChEBI ID

CHEBI:17553

CAS Number

CAS 1071-23-4

TTD Drug ID

DM3O9YW

General Information of Drug (ID: DM3O9YW)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein kinase C beta (PRKCB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[2]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Lymphoma	2A80-2A86	Phase 3	[3]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[4]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
MS-553	DM7ER9J	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[6]
Linetastine	DMF8B62	Rhinitis	FA20	Discontinued in Phase 2	[7]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[8]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[9]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[10]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
3	Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
4	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
5	Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
6	ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
7	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
8	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
9	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
10	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
11	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.